Approaches and Challenges of Valuing of Next Generation Sequencing (NGS) in Precision Health using Preferences

17 February 2021

Even in the era of precision health, the implementation of next generation sequencing (NGS) into clinical practice has been variable. There have been few economic studies that have examined patient preferences that reflect both health and nonhealthy outcomes associated with NGS. The complexity of information, uncertainty, multiple risks and potential downstream consequences from NGS testing makes it challenging to fully assess its value.  Preference methods continue to grow in their relevance and application in health as a powerful tool for including the patient voice in clinical decision making and health policy to increase patient-centeredness. This presentation will focus on preferences studies and examples of how they can be used in a variety of applications ranging from identifying patient-relevant outcomes, valuing patient-reported outcomes, prioritizing important measures of quality of care, and facilitating deliberations in both the clinical and health policy context, particularly with respect to precision medicine and next generation sequencing. 

Approaches and Challenges of Valuing of Next Generation Sequencing (NGS) in Precision Health using Preferences

Presenter

Deborah has experience in technology assessment agencies, academia and pharmaceutical and diagnostics industry research settings in Canada, the United States, and Europe. Dr Marshall focuses her research program on methods to assesses the value of health care interventions through measurement of patient preferences, cost-effectiveness analysis, and simulation modeling of health care with a focus on precision medicine. Dr. Marshall is the co-lead of the Economics platform for 3 national precision health projects funded by CIHR and Genome Canada: UCAN CANDU – Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease, UCAN CURE - Precision Decisions for Childhood Arthritis and C4R SOLVE (Care4Rare Canada: Harnessing multi-omics to deliver innovative diagnostic care for rare genetic diseases in Canada). Dr. Marshall is an author of several Good Research Practice Task Force Reports of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).